Adar1 Capital Management, LLC Portfolio Holdings

Adar1 Capital Management, LLC

  • $1.06 Trillion
  • Q3 2025

Adar1 Capital Management, LLC has filed its 13F form on November 14, 2025 for Q3 2025 where it was disclosed a total value porftolio of $1.06 Trillion distributed in 220 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Abivax Sa with a value of $115B, Keros Therapeutics, Inc. with a value of $85.3B, Protagonist Therapeutics, Inc with a value of $65.7B, Roivant Sciences Ltd. with a value of $50.6B, and Ea Series Trust with a value of $38.4B.

Examining the 13F form we can see an increase of $412B in the current position value, from $652B to 1.06T.

Adar1 Capital Management, LLC is based out at Austin, TX

Below you can find more details about Adar1 Capital Management, LLC portfolio as well as his latest detailed transactions.

Portfolio value $1.06 Trillion
Healthcare: $648 Billion
ETFs: $83.7 Billion
Communication Services: $996 Million
Consumer Cyclical: $989 Million
Technology: $689 Million
Financial Services: $531 Million
Basic Materials: $312 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
Abivax Sa
-
$115 Billion 10.77% of portfolio
-
Q3 2025 Reduced 56.02%
$445M
$85.3 Billion 8.01% of portfolio
5,389,264
Q2 2025 Added 262.56%
$4.15B
$65.7 Billion 6.17% of portfolio
989,182
Q3 2025 Added 4.34%
$14.3B
$50.6 Billion 4.76% of portfolio
3,347,501
Q3 2025 Added 72.48%
Ea Series Trust
-
$38.4 Billion 3.61% of portfolio
-
Q1 2025 Added 3.59%
$0
$36.4 Billion 3.42% of portfolio
54,684
Q3 2025 Added 141.07%
$3.55B
$36.1 Billion 3.39% of portfolio
2,241,753
Q3 2025 Added 318.97%
$690M
$31.1 Billion 2.92% of portfolio
2,113,153
Q3 2025 Added 141.23%
$2.13B
$29.4 Billion 2.77% of portfolio
868,780
Q3 2025 Added 2.16%
$6.25B
$28.5 Billion 2.68% of portfolio
518,921
Q3 2025 Reduced 10.86%
Septerna Inc
-
$22.1 Billion 2.08% of portfolio
-
Q3 2025 Added 38.86%
$481M
$14.3 Billion 1.35% of portfolio
1,469,098
Q3 2025 Reduced 56.47%
$9.84B
$14.2 Billion 1.33% of portfolio
273,414
Q3 2025 Added 5.3%
$678M
$13.2 Billion 1.24% of portfolio
2,903,226
Q3 2025 Added 2.74%
Rapt Therapeutics Inc
-
$13.1 Billion 1.23% of portfolio
-
Q3 2025 Reduced 35.17%
$255M
$12.9 Billion 1.21% of portfolio
4,045,414
Q3 2025 Added 31.28%
$743M
$11.8 Billion 1.11% of portfolio
866,202
Q3 2025 Reduced 28.12%
Bioage Labs Inc
-
$11.1 Billion 1.04% of portfolio
-
Q3 2025 Reduced 2.95%
Monopar Therapeutics Inc
-
$10.6 Billion 1.0% of portfolio
-
Q3 2025 Added 28.75%
$2.34B
$10.3 Billion 0.97% of portfolio
248,368
Q3 2025 Added 367.52%
Lexeo Therapeutics Inc
-
$10.2 Billion 0.96% of portfolio
-
Q3 2025 Added 955.73%
Cg Oncology Inc
-
$10 Billion 0.94% of portfolio
-
Q3 2025 Reduced 52.43%
$204M
$9.27 Billion 0.87% of portfolio
2,835,680
Q3 2025 Reduced 5.79%
$74.3B
$8.83 Billion 0.83% of portfolio
15,700
Q3 2025 Added 367.12%
$10.2B
$8.75 Billion 0.82% of portfolio
133,818
Q3 2025 Reduced 9.86%
$1.22B
$8.58 Billion 0.81% of portfolio
351,032
Q3 2025 Added 465.38%
Inhibikase Therapeutics Inc
-
$8.5 Billion 0.8% of portfolio
-
Q3 2025 Added 2.45%
$505M
$8.11 Billion 0.76% of portfolio
7,370,987
Q3 2025 New
$35M
$7.95 Billion 0.75% of portfolio
5,559,988
Q3 2025 New
Metsera Inc
-
$7.98 Billion 0.75% of portfolio
-
Q3 2025 New
Perceptive Cap Solutions Cor
-
$7.92 Billion 0.74% of portfolio
-
Q2 2024 New
$1.4B
$7.78 Billion 0.73% of portfolio
133,316
Q3 2025 New
$2.87B
$7.67 Billion 0.72% of portfolio
213,064
Q3 2025 Added 117.34%
$385M
$7.67 Billion 0.72% of portfolio
815,975
Q3 2025 Reduced 17.52%
$2.54B
$7.59 Billion 0.71% of portfolio
189,098
Q3 2025 Reduced 27.13%
$11.4B
$7.23 Billion 0.68% of portfolio
36,345
Q3 2025 Added 2,492.37%
$495M
$7.1 Billion 0.67% of portfolio
1,988,288
Q3 2025 Reduced 44.78%
$1.65B
$6.74 Billion 0.63% of portfolio
349,807
Q3 2025 Added 66.33%
$5.94B
$6.5 Billion 0.61% of portfolio
139,136
Q3 2025 Added 3.73%
Aa Mission Acquisition Corp
-
$6.08 Billion 0.57% of portfolio
-
Q1 2025 Added 3.24%
Bridgebio Oncology Therapeut
-
$5.8 Billion 0.55% of portfolio
-
Q3 2025 New
$6.52B
$5.49 Billion 0.52% of portfolio
51,450
Q3 2025 Added 80.84%
$28.2B
$5.41 Billion 0.51% of portfolio
267,816
Q3 2025 Reduced 22.57%
Oaktree Acquisition Corp Iii
-
$5.48 Billion 0.51% of portfolio
-
Q1 2025 Added 3.3%
$5.54B
$5.01 Billion 0.47% of portfolio
49,571
Q3 2025 Added 9.21%
$664M
$4.83 Billion 0.45% of portfolio
913,242
Q3 2025 New
$21.2B
$4.7 Billion 0.44% of portfolio
11,200
Q3 2025 New
$3.05B
$4.62 Billion 0.43% of portfolio
175,919
Q3 2025 Added 159.42%
Bridgebio Pharma Inc
-
$4.45 Billion 0.42% of portfolio
-
Q3 2025 Reduced 99.0%

Summary

  • Portfolio
  • No. of Stocks 220
  • Current Value $1.06 Trillion
  • Prior Value $652 Billion
  • Filing
  • Period Q3 2025
  • Filing Date November 14, 2025
  • Form Type 13F-HR
  • Activity in Q3 2025
  • New Purchases 47 stocks
  • Additional Purchases 67 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 52 stocks
Track This Portfolio

Track Adar1 Capital Management, LLC Portfolio

Follow Adar1 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email